Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PFNX - Pfenex Inc.


Previous close
12.75
0   0%

Share volume: 0
Last Updated: Wed 30 Sep 2020 06:00:00 AM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%

$12.75
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
24%
Profitability 50%
Dept financing 5%
Liquidity 35%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$12.75
P/E Ratio 
N/A
DAY RANGE
$12.75 - $12.75
EPS 
-$0.22
52 WEEK RANGE
$5.26 - $14.00
52 WEEK CHANGE
$63.25
MARKET CAP 
437.282 M
YIELD 
N/A
SHARES OUTSTANDING 
34.297 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$34,151,971
AVERAGE 10 VOLUME 
$1,634,313
AVERAGE 30 VOLUME 
$900,714
Company detail
CEO: Evert B. Schimmelpennink
Region: US
Website: http://www.pfenex.com
Employees: 81
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Biotechnology
Sector: Health Technology

Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.

Recent news